The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung ...

In this article, we will take a look at the 12 stocks that will double in 2025.

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

Starbucks Corporation SBUX gained 5.7% to $106.15 following better-than-expected quarterly financial results. Additionally, ...

Sidney, a book developer and publisher, announced today the publication of YOU ARE THE DOCTOR: The Importance of a Team Approach in Cancer Treatment by the late Susan Finlay Dunbar, MD. A unique ...

SolarBank Corporation (Cboe CA: SUNN) ("SolarBank" or the "Company") today announces highlights and new milestones reached during the 2024 calendar year.  The company remains committed to pioneering ...

The owner of the Los Angeles Times discusses his fight to cure cancer and why he wants President Donald Trump to succeed in ...

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.